Peptides and Bloodwork: What Labs to Monitor, Legal Status, Drug Testing, and Administration

What Blood Tests Do You Need Before Starting Peptide Therapy?

A baseline blood panel before peptide therapy is not optional. It establishes the reference values against which every future lab draw is compared and catches pre-existing conditions that change which peptide is appropriate or safe. The minimum panel includes IGF-1, fasting glucose, HbA1c, a complete metabolic panel (CMP), CBC with differential, a full lipid panel, and TSH. Depending on the peptide chosen, additional markers matter.

For growth-hormone secretagogues (GHS) such as sermorelin, ipamorelin, CJC-1295, and tesamorelin, IGF-1 is the single most important pre-treatment lab. The Endocrine Society's 2011 clinical practice guideline on growth hormone deficiency specifies that IGF-1 should be measured before initiating GH-axis therapy and used to titrate dosing to keep levels within the age-adjusted normal range [1]. An IGF-1 above the upper limit of normal before you even start therapy is a contraindication.

Fasting glucose and HbA1c are required before any GHS because supraphysiologic GH can induce insulin resistance. The FDA label for tesamorelin (Egrifta) explicitly states that patients should be monitored for glucose intolerance and new-onset diabetes mellitus [2]. If fasting glucose already exceeds 100 mg/dL, the prescriber needs that datum before choosing a starting dose.

For GLP-1 receptor agonists such as semaglutide and tirzepatide, the American Diabetes Association (ADA) 2024 Standards of Care recommend HbA1c at baseline and then every 3 months until stable [3]. Lipase and amylase are worth checking if the patient has any history of pancreatitis, given the FDA's boxed-warning language on GLP-1 agents regarding this risk [4].

For peptides with primarily tissue-repair or anti-inflammatory actions, such as BPC-157 or TB-500, there are no established clinical monitoring protocols because these compounds lack FDA approval and have not completed Phase III human trials. Prudent clinical practice still calls for a CMP to assess renal and hepatic function before use.

The thyroid panel (TSH, free T4) matters because growth hormone increases conversion of T4 to T3 via hepatic deiodinase activity. Patients with subclinical hypothyroidism may experience worsening on GHS therapy without a thyroid baseline [5].

Which Lab Values Change During Peptide Therapy, and By How Much?

Specific peptides shift specific markers in measurable, predictable ways. Knowing the expected direction and magnitude helps distinguish a therapeutic effect from a pathologic change.

IGF-1 rises on all GHS peptides. In a randomized trial of sermorelin in healthy older adults, 26 weeks of sermorelin 0.02 mg/kg/day produced a mean IGF-1 increase of approximately 30% from baseline [6]. Ipamorelin at 200 mcg three times daily produced similar IGF-1 elevations without the cortisol or prolactin spikes seen with GHRP-6 [7]. The target IGF-1 range most prescribers use is 150-350 ng/mL; exceeding 400 ng/mL warrants a dose reduction.

Fasting glucose may rise modestly on GHS therapy. Tesamorelin's Phase III trials (NAIL and LIPO-010, combined N=816) showed a mean fasting glucose increase of 5-7 mg/dL versus placebo after 26 weeks [8]. The increase was generally not clinically significant in non-diabetic patients, but monitoring is still warranted at 6 weeks.

HbA1c falls measurably on GLP-1 agonists. In the SUSTAIN-6 trial (N=3,297), semaglutide 0.5 mg and 1.0 mg weekly reduced HbA1c by 1.1% and 1.4% respectively versus 0.4% for placebo at 104 weeks [9]. Tirzepatide's SURPASS-2 trial (N=1,879) showed HbA1c reductions of 2.01% to 2.30% versus 1.86% for semaglutide 1 mg [10].

LDL cholesterol typically falls on semaglutide. SUSTAIN-6 showed a statistically significant 4.3% reduction in LDL versus placebo [9]. This does not eliminate the need for a lipid recheck, because individual responses vary.

Liver enzymes (ALT, AST) may decrease on GLP-1 therapy in patients with non-alcoholic fatty liver disease. A 2021 meta-analysis in The Lancet Gastroenterology and Hepatology covering 6 randomized trials showed semaglutide significantly reduced liver fat content versus placebo (P<0.001) [11].

Prolactin and cortisol are worth checking on GHRP-class peptides. GHRP-6 and GHRP-2 raise ACTH and cortisol transiently; ipamorelin does not, which is one clinical reason to prefer it [7].

The table below summarizes the recommended monitoring schedule used by the HealthRX clinical team. This framework consolidates published guideline recommendations with prescriber consensus where trial data are absent.

| Peptide Class | Baseline | Week 6 | Week 12 | Annually | |---|---|---|---|---| | GHS (sermorelin, ipamorelin, CJC-1295) | IGF-1, fasting glucose, HbA1c, CMP, CBC, TSH, lipids | IGF-1, fasting glucose | IGF-1, HbA1c, CMP | Full panel | | Tesamorelin (Egrifta) | Same as GHS + waist circumference | Fasting glucose, IGF-1 | IGF-1, HbA1c, lipids | Full panel | | GLP-1 agonists (semaglutide, tirzepatide) | HbA1c, fasting glucose, lipids, CMP, lipase, amylase | HbA1c, fasting glucose | HbA1c, lipids, CMP | Full panel | | BPC-157, TB-500 (research use) | CMP, CBC | CMP | CMP | CMP, CBC | | PT-141 (bremelanotide) | CMP, CBC, blood pressure | Blood pressure | CMP | Full panel |

Are Peptides Legal in the United States?

The legal status of peptides in the US depends entirely on which peptide, how it is dispensed, and for what purpose. The short answer is that FDA-approved peptides are legal by prescription, while research-only peptides are not approved for human use and cannot legally be sold for that purpose.

The FDA has approved several peptides for specific clinical indications. Semaglutide (Ozempic, Wegovy) carries approval for type 2 diabetes and chronic weight management [12]. Tirzepatide (Mounjaro, Zepbound) is approved for type 2 diabetes and obesity [13]. Tesamorelin (Egrifta SV) is approved for HIV-associated lipodystrophy [2]. Bremelanotide (Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women [14].

Peptides such as BPC-157, TB-500 (thymosin beta-4), ipamorelin, and CJC-1295 are not FDA-approved for any human indication. The FDA classifies them as research chemicals. In 2022, the FDA issued guidance indicating that certain peptides, including BPC-157, may not be compounded under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act because they are "essentially a copy" of a drug or do not meet compounding criteria [15]. This guidance significantly narrowed availability through US compounding pharmacies.

WADA (World Anti-Doping Agency) prohibits a wide range of peptides in sport, including all GHS peptides, GHRP class compounds, and growth hormone-releasing hormones under its Prohibited List [16]. Athletes subject to WADA testing should treat all peptides as banned absent explicit clearance.

State law adds another layer. Some states have stricter pharmacy compounding regulations than federal baseline rules. Patients should verify with their prescriber and pharmacy whether their specific peptide is currently available through a licensed 503A compounding pharmacy in their state.

Can Peptides Show Up on a Drug Test?

Standard workplace drug screens do not test for peptides. The SAMHSA-5 panel, which covers marijuana, cocaine, opiates, amphetamines, and phencyclidine, has no peptide analytes [17]. Extended panels that add barbiturates, benzodiazepines, or opioid metabolites also do not include peptides.

Military and federal employee drug testing panels use SAMHSA guidelines as their basis. These panels similarly do not include any peptide analytes [17].

Athletic drug testing is a different story. WADA's 2024 Prohibited List explicitly bans growth hormone releasing hormones (including CJC-1295, sermorelin, tesamorelin), growth hormone secretagogues (including ipamorelin, GHRP-2, GHRP-6), and GLP-1 receptor agonists when not used for documented medical necessity [16]. WADA-accredited labs use liquid chromatography-mass spectrometry and immunoassay methods capable of detecting peptides at nanogram-per-milliliter concentrations. Detection windows vary: short peptides like GHRP-6 may be detectable for 24-48 hours post-injection, while longer-acting molecules like semaglutide (half-life approximately 7 days) could remain detectable for weeks [18].

Bremelanotide (PT-141) would not appear on a standard SAMHSA drug screen. No publicly available data confirm its detection on WADA panels for sports not explicitly testing melanocortin agonists.

The practical takeaway: if your concern is a workplace or probation drug test, peptides will not appear. If you compete in any sport governed by WADA, USADA, or a WADA-compliant federation, many peptides are prohibited and detectable.

How Much Do Peptide Injections Hurt?

Subcutaneous peptide injections using correct technique are minimally painful for most patients, typically rated 1-2 out of 10. The pain experience depends on needle gauge, injection site, peptide formulation pH, injection speed, and the patient's own technique consistency.

Most subcutaneous peptide injections use a 29-31 gauge needle, 4-8 mm in length. A 31-gauge needle has an outer diameter of 0.26 mm, compared to 0.45 mm for a 26-gauge needle. The difference is clinically meaningful for pain perception. A 2019 randomized crossover study in Diabetes Care comparing 29-gauge and 31-gauge insulin pen needles (a valid proxy for subcutaneous peptide injection technique) showed that 31-gauge needles produced significantly lower pain scores (mean visual analog scale 1.4 vs. 2.1, P<0.05) [19].

The abdomen 2 inches from the navel, the anterior thigh, and the lateral deltoid are the standard injection sites. The abdomen is the most commonly used site for GHS peptides because subcutaneous tissue depth is generally sufficient. Rotating sites prevents lipohypertrophy, a condition in which repeated injections at the same site cause fibrous subcutaneous nodules that alter absorption and increase discomfort [20].

pH of the reconstituted peptide solution also affects pain. Bacteriostatic water (which contains 0.9% benzyl alcohol) is the standard diluent for lyophilized peptides. The benzyl alcohol acts as a preservative but also as a mild local anesthetic, which reduces injection-site stinging compared to sterile water alone [21].

Slow injection technique (5-10 seconds per 0.1 mL) disperses the solution over a larger subcutaneous area and reduces the pressure-mediated discomfort of rapid bolus delivery. Letting refrigerated peptide solution reach room temperature before injection also lowers pain scores by preventing cold-induced vasoconstriction at the site.

Post-injection erythema or mild induration lasting less than 30 minutes is normal. Persistent swelling, warmth, or pain lasting beyond 24 hours warrants evaluation for injection-site infection or sterile abscess, which can occur if aseptic technique is not followed rigorously.

Can Peptides Be Taken Orally?

Most peptides cannot be effectively absorbed through the gastrointestinal tract in their unmodified form. Oral bioavailability for standard peptides is generally below 2% because gastric acid and peptidases (pepsin, trypsin, chymotrypsin) cleave the amino acid bonds before the molecule can cross the intestinal epithelium [22].

The GI tract is designed to break proteins and peptides into individual amino acids for absorption. A peptide that survives gastric acid still faces brush-border peptidases at the intestinal lumen and then tight junctions that limit paracellular transport for molecules above roughly 500 Daltons. Most therapeutic peptides are 500-5,000 Daltons.

Pharmaceutical chemistry has partially solved this problem in a few cases. Oral semaglutide (Rybelsus, 3-7-14 mg tablets) uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to transiently increase gastric pH and promote transcellular absorption directly through the gastric mucosa. The PIONEER-1 trial (N=703) showed that oral semaglutide 14 mg daily reduced HbA1c by 1.4% versus 0% for placebo at 26 weeks, confirming meaningful systemic absorption via this mechanism [23]. Oral bioavailability with SNAC reaches approximately 1%, which sounds low but is sufficient given the drug's potency.

Cyclic peptides and N-methylated peptides show better oral stability because backbone methylation blocks peptidase attack. Cyclosporine (an 11-amino-acid cyclic peptide) achieves 20-50% oral bioavailability through this mechanism combined with lipophilicity that aids membrane permeation [24].

Collagen peptides (hydrolyzed collagen supplements) are short di- and tri-peptides that survive digestion. A 2019 randomized controlled trial in the Journal of Cosmetic Dermatology (N=72) showed that oral hydrolyzed collagen 2.5 g/day for 12 weeks significantly increased skin elasticity versus placebo [25]. These are not therapeutic peptides in the clinical sense, but they demonstrate that small peptides can reach systemic circulation orally.

For research-grade peptides such as BPC-157, some practitioners use oral or sublingual administration. BPC-157 has demonstrated bioactivity via oral routes in animal models, including a 2018 study in rats showing gastroprotective effects after oral administration [26]. Human pharmacokinetic data for oral BPC-157 are not available in peer-reviewed literature as of early 2025.

Nasal and sublingual routes offer intermediate bioavailability for some peptides. PT-141 (bremelanotide) was originally developed as a nasal spray but reformulated as a subcutaneous auto-injector for better dose consistency after variable absorption was observed with intranasal delivery [14].

How to Interpret Your IGF-1 Lab Result on a Growth-Hormone Secretagogue

IGF-1 reference ranges are age-dependent and assay-dependent. A result that looks "normal" on one lab's reference range may be subtherapeutic or supraphysiologic on another's. Always compare your result to the age-matched reference interval provided by the specific laboratory that ran the test.

The Endocrine Society guideline recommends maintaining IGF-1 in the normal age-adjusted range during GH-axis therapy and avoiding levels above the upper limit of normal [1]. For a 45-year-old male, the typical reference range is 88-246 ng/mL on the Quest Diagnostics IGF-1 assay. A value of 300 ng/mL in that patient represents a mild excess and warrants dose reduction.

Timing of the IGF-1 draw matters. IGF-1 is relatively stable throughout the day compared to GH (which pulses), but the Endocrine Society recommends drawing IGF-1 in a fasted or consistently timed state to reduce variability [1]. Most practitioners draw it in the morning before eating.

If IGF-1 remains low-normal after 8-12 weeks on a GHS peptide, two explanations are most common: insufficient dose, or inadequate endogenous GH reserve. The latter is evaluated by provocative GH stimulation testing (GHRH-arginine or glucagon stimulation) if clinically indicated [1].

A single elevated IGF-1 does not confirm pathology. Repeat it before changing therapy. Exercise in the 24 hours before the draw can transiently raise IGF-1 by 10-15% [27].

What Is the Risk of Hyperglycemia on Peptide Therapy?

Growth-hormone secretagogues carry a real, dose-dependent risk of impaired glucose tolerance. GH's counter-regulatory effects on insulin are well established: GH reduces glucose uptake in peripheral tissues and increases hepatic glucose output, effects that are mediated in part through GH receptor signaling in liver and muscle [28].

In tesamorelin's Phase III program, new-onset diabetes occurred in approximately 4.5% of treated patients versus 1.3% of placebo over 52 weeks [8]. This risk is low in absolute terms but not negligible, particularly in patients with pre-diabetes (fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4%) at baseline.

Patients with pre-diabetes who elect GHS therapy should recheck fasting glucose at 6 weeks. If fasting glucose rises above 126 mg/dL on two separate measurements, the prescriber must address that finding before continuing therapy. The ADA's 2024 Standards of Care define the diagnostic threshold for diabetes as fasting plasma glucose of 126 mg/dL or above on two separate occasions [3].

GLP-1 receptor agonists, by contrast, reduce hyperglycemia risk. They stimulate insulin secretion in a glucose-dependent manner, meaning they do not cause hypoglycemia at therapeutic doses when used as monotherapy [3].